GPh 301Alternative Names: GPh-301
Latest Information Update: 18 Dec 2015
At a glance
- Originator GEROPHARM
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Endocrine disorders
Most Recent Events
- 18 Dec 2015 Preclinical trials in Endocrine disorders in Russia (unspecified route) (GEROPHARM pipeline, December 2015)